How the Body Makes Glucosamine: Glucose, Glutamine and ATP

Table of Contents

1. Overview: Your Body Makes Its Own Glucosamine
2. The Three Starting Ingredients
3. The Process, Step by Step
4. The Whole Recipe in One Line
5. What Happens Next: From Glucosamine to UDP-GlcNAc
6. What the Body Builds With It
7. The Brake: How the Cell Limits Production
8. A Sugar Sensor: Why This Pathway Matters for Blood Sugar
9. Where Supplement Glucosamine Enters
10. What This Means for Glucosamine Supplements
11. What Is Not Known
12. Key Research Papers
13. Connections
14. Featured Videos

Overview: Your Body Makes Its Own Glucosamine

Glucosamine is an amino sugar: a glucose molecule in which one oxygen-and-hydrogen group (the hydroxyl on carbon 2) has been swapped for a nitrogen group. That one swap changes what the sugar can do. Glucose is burned for energy; glucosamine is a building block.

The body does not need to eat glucosamine to have it. It makes it inside the cell, in the watery interior called the cytoplasm, through a short route biochemists call the hexosamine biosynthesis pathway. The pathway is a side road off glycolysis, the main road cells use to burn glucose. In the words of a 2006 review, it is "a relatively minor branch of glycolysis" that takes about 3% of the glucose a cell uses (Buse 2006). The rest, roughly 97%, goes on to be burned for energy or stored.

The first committed step is run by a single enzyme, GFAT (glutamine:fructose-6-phosphate amidotransferase, also called glucosamine-6-phosphate synthase). GFAT is the gatekeeper: it decides how much glucosamine the cell makes, and it is held in check by the pathway's own end product (Milewski 2002; Ruegenberg 2020).

Back to Table of Contents

The Three Starting Ingredients

None of the three has to come from a supplement. Glucose comes from carbohydrate in food and from the liver. ATP is made constantly by every cell. Glutamine is made by the body in large amounts, mainly by muscle; see how the body makes its own glutamine.

Back to Table of Contents

The Process, Step by Step

Step 1: Glucose is phosphorylated

• Reaction: Glucose + ATP → Glucose-6-phosphate + ADP
• Enzyme: Hexokinase
• Cofactor: Magnesium (Mg²⁺)
• What happens: a phosphate group from ATP is attached to carbon 6 of glucose. The charged phosphate traps the sugar inside the cell; it can no longer leak back out through the glucose transporters.

Step 2: The sugar is rearranged

• Reaction: Glucose-6-phosphate ⇌ Fructose-6-phosphate
• Enzyme: Phosphoglucose isomerase
• What happens: the atoms are rearranged, with nothing added or removed. The reaction runs both ways. This is the fork in the road: most fructose-6-phosphate continues down glycolysis to be burned for energy, and only a small share, about 3%, is taken by GFAT to make glucosamine (Buse 2006).

Step 3: The nitrogen is added, and glucosamine is formed

• Reaction: Fructose-6-phosphate + Glutamine → Glucosamine-6-phosphate + Glutamate
• Enzyme: GFAT (glutamine:fructose-6-phosphate amidotransferase)
• What happens: GFAT pulls the amide nitrogen off glutamine and attaches it to the sugar, and in the same reaction turns the fructose ring back into a glucose-type ring. It is an unusual enzyme: it does both an amino transfer and a sugar rearrangement, and unlike its relatives it cannot use free ammonia, only glutamine (Milewski 2002).
• Why it matters: this is the rate-limiting step, the one that sets how much glucosamine the cell makes (Buse 2006; Marshall 1991).

Result

Glucosamine-6-phosphate is the form of glucosamine the body makes. It is an amino sugar: glucose with a nitrogen group in place of the hydroxyl group on carbon 2, still carrying the phosphate tag from Step 1.

Back to Table of Contents

The Whole Recipe in One Line

Glucose + ATP + Glutamine → Glucosamine-6-phosphate + ADP + Glutamate

Read left to right, the equation says three things:

• The carbon comes from sugar. All six carbons of glucosamine started as blood glucose.
• The nitrogen comes from an amino acid. Glutamine gives up one nitrogen and becomes glutamate, which the cell can recycle back into glutamine.
• It costs energy. One ATP is spent in Step 1. ADP is recharged to ATP by the mitochondria.

Because both glucose and glutamine feed GFAT, the rate of glucosamine production rises when more of either is around. That is what lets the pathway act as a gauge of how well fed the cell is, and it is the root of the blood-sugar story below.

Back to Table of Contents

What Happens Next: From Glucosamine to UDP-GlcNAc

Glucosamine-6-phosphate does not stay as it is for long. Three more steps finish the job (Buse 2006):

1. An acetyl group from acetyl-CoA is added, giving N-acetylglucosamine-6-phosphate (GlcNAc-6-P).
2. The phosphate moves from carbon 6 to carbon 1, giving N-acetylglucosamine-1-phosphate.
3. The sugar is joined to UTP, a cousin of ATP, giving UDP-N-acetylglucosamine, or UDP-GlcNAc.

UDP-GlcNAc is the real end product: an "activated" amino sugar ready to be clipped onto proteins and fats. Some of it is converted into its close cousin UDP-N-acetylgalactosamine (the same atoms, flipped at one carbon), the amino sugar in chondroitin. The diagram below shows where it goes and the feedback brake that keeps the pathway in check.

Back to Table of Contents

What the Body Builds With It

The amino sugars made by this pathway are, in Buse's words, "essential building blocks for glycosyl side chains, of proteins and lipids" (Buse 2006). In plain terms:

• Joint fluid and cartilage. Hyaluronan, the slippery molecule in joint fluid, is a long chain of alternating glucuronic acid and N-acetylglucosamine. Chondroitin sulfate in cartilage uses the galactosamine cousin. This is the source of the idea behind glucosamine supplements.
• Mucus and protective linings. The mucins that coat the gut, airways and eyes are heavily sugar-coated proteins, and their sugar chains start from these amino sugars.
• Sugar-coated proteins everywhere. Most proteins on the cell surface and in the blood, including hormone receptors and antibodies, carry sugar chains that contain N-acetylglucosamine.
• A signal inside the cell. Thousands of proteins in the nucleus and cytoplasm are tagged and untagged with single N-acetylglucosamine units, called O-GlcNAc. This cycling "serves as a nutrient and stress sensor" and competes with phosphate for the same spots on proteins (Hart 2007).

The point for supplements is simple: the body's demand for these building blocks is met by its own production line, which runs every hour of every day in every tissue.

Back to Table of Contents

The Brake: How the Cell Limits Production

A pathway that turns sugar into building blocks needs a limit, or a meal high in sugar would flood the cell with amino sugars. The limit sits at GFAT.

• Feedback from the end product. UDP-GlcNAc "directly interacts with GFAT-1, inhibiting catalytic activity" (Ruegenberg 2020). When the cell has enough, production slows.
• Hormonal tuning. Protein kinase A, part of the cell's response to hormones such as glucagon and adrenaline, changes how strongly GFAT responds to that feedback (Ruegenberg 2021).
• A short-lived enzyme. In fat cells, blocking new protein production quickly shut down the glucose-induced effects of the pathway, evidence that GFAT itself is turned over rapidly and has to be continually remade (Marshall, Bacote and Traxinger, June 1991).

This brake is why eating more glucose or glutamine does not turn the pathway into a big "sugar sink". It is built to sense supply, not to dispose of it.

Back to Table of Contents

A Sugar Sensor: Why This Pathway Matters for Blood Sugar

In 1991, Stephen Marshall's group in Memphis was studying why fat cells bathed in high glucose stop responding to insulin. They found that the effect needed three things together: glucose, insulin and glutamine. Drugs that block GFAT prevented it. Their conclusion was that "the routing of incoming glucose through the hexosamine biosynthesis pathway plays a key role in the development of insulin resistance" (Marshall 1991). Later that year they described the pathway as "a glucose sensor coupled to a negative feedback system that can limit the extent of glucose uptake" (Marshall, Garvey and Traxinger 1991).

The idea was then tested in animals:

• Mice engineered to make about 2.4 times more GFAT in muscle became insulin resistant, clearing glucose at roughly half the normal rate (Hebert 1996).
• The activity of GFAT has been found to track with how fast normal humans and transgenic mice clear glucose (McClain and Crook 1996).
• More flux through the pathway is "required and sufficient" for several of the harmful effects of sustained high glucose on heart, blood-vessel and kidney cells in laboratory studies (Buse 2006).

So the pathway that makes glucosamine is not just a factory. It is one of the ways a cell senses that it is over-supplied with sugar, and one of its responses is to take in less glucose. Read the full story, including the human studies that point both ways, on Glucosamine, Blood Sugar and Diabetes.

Back to Table of Contents

Where Supplement Glucosamine Enters

Swallowed glucosamine is absorbed, carried in the blood, taken into cells and tagged with phosphate. That puts it straight into the pathway at glucosamine-6-phosphate, after GFAT, so the brake described above never gets a say.

In Marshall's fat-cell experiments, glucosamine caused insulin resistance on its own, without glutamine and even when GFAT was blocked. They estimated glucosamine was "at least 40 times more potent than glucose" at causing it (Marshall 1991). These were cells in a dish exposed to much higher levels than a supplement produces in human blood: after a 1,500 mg dose, blood glucosamine peaked at about 2 to 12 micromoles per litre (Biggee 2006). The human studies of oral doses are mixed, and they are covered in detail on the blood sugar page.

A common idea follows: if the body makes glucosamine from glucose and glutamine, why not take glutamine and let the body do the work? That question has its own page, Glutamine Instead of Glucosamine?

Back to Table of Contents

What This Means for Glucosamine Supplements

• The body already makes it. Every tissue runs this pathway from glucose and glutamine, both of which the body supplies itself.
• The joint benefit has not held up. Large independent trials and current guidelines do not support it; see what the trials found.
• It enters past the brake. Supplement glucosamine skips the step the cell uses to limit production, and the pathway it feeds is the one that signals sugar overload.
• High blood sugar. The concern from this pathway applies most to people with diabetes, prediabetes, high fasting glucose or a raised HbA1c. The human evidence is mixed: some studies found higher glucose or insulin resistance, others found no change.

Fasting glucose and HbA1c are the measurements the human studies used; decisions about any supplement, especially alongside diabetes medicines or warfarin, belong with a clinician. See also Glucosamine Safety.

Back to Table of Contents

What Is Not Known

• The exact share in each tissue. The often-quoted figure of about 3% of glucose comes from early cell studies; the true share varies by tissue and by how well fed the cell is.
• How much the body makes per day. There is no good human estimate of total daily glucosamine production, so no one can say what fraction a supplement adds.
• Cells versus people. Much of the sensor story comes from cells and rodents at high exposures. How far it applies to a person swallowing 1,500 mg a day is the open question the human trials try to answer.

Back to Table of Contents

Key Research Papers

1. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. Journal of Biological Chemistry. 1991;266(8):4706-4712. — PubMed PMID: 2002019
2. Marshall S, Bacote V, Traxinger RR. Complete inhibition of glucose-induced desensitization of the glucose transport system by inhibitors of mRNA synthesis. Evidence for rapid turnover of glutamine:fructose-6-phosphate amidotransferase. Journal of Biological Chemistry. 1991;266(16):10155-10161. — PubMed PMID: 2037572
3. Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB Journal. 1991;5(15):3031-3036. — doi:10.1096/fasebj.5.15.1743436 (PubMed PMID: 1743436)
4. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. American Journal of Physiology-Endocrinology and Metabolism. 2006;290(1):E1-E8. — doi:10.1152/ajpendo.00329.2005 (PubMed PMID: 16339923)
5. Milewski S. Glucosamine-6-phosphate synthase—the multi-facets enzyme. Biochimica et Biophysica Acta. 2002;1597(2):173-192. — doi:10.1016/s0167-4838(02)00318-7 (PubMed PMID: 12044898)
6. Ruegenberg S, Horn M, Pichlo C, et al. Loss of GFAT-1 feedback regulation activates the hexosamine pathway that modulates protein homeostasis. Nature Communications. 2020;11(1):687. — doi:10.1038/s41467-020-14524-5 (PubMed PMID: 32019926)
7. Ruegenberg S, Mayr FAMC, Atanassov I, et al. Protein kinase A controls the hexosamine pathway by tuning the feedback inhibition of GFAT-1. Nature Communications. 2021;12(1):2176. — doi:10.1038/s41467-021-22320-y (PubMed PMID: 33846315)
8. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446(7139):1017-1022. — doi:10.1038/nature05815 (PubMed PMID: 17460662)
9. McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes. 1996;45(8):1003-1009. — doi:10.2337/diab.45.8.1003 (PubMed PMID: 8690144)
10. Hebert LF Jr, Daniels MC, Zhou J, et al. Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. Journal of Clinical Investigation. 1996;98(4):930-936. — doi:10.1172/JCI118876 (PubMed PMID: 8770864)
11. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Annals of the Rheumatic Diseases. 2006;65(2):222-226. — doi:10.1136/ard.2005.036368 (PubMed PMID: 16079170)

PubMed Topic Searches

1. PubMed: The hexosamine biosynthesis pathway and GFAT
2. PubMed: UDP-GlcNAc feedback on GFAT
3. PubMed: The hexosamine pathway and insulin resistance
4. PubMed: O-GlcNAc as a nutrient sensor

This content is provided for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning or stopping any supplement.

Back to Table of Contents

Connections

• All Amino Acids
• Glucosamine
• Glucosamine, Blood Sugar and Diabetes
• Glutamine Instead of Glucosamine?
• Glucosamine for Joint Pain
• History of Glucosamine
• Glucosamine Safety
• Glutamine
• How the Body Makes Glutamine
• Collagen
• Magnesium
• Insulin Resistance
• Prediabetes
• Type 2 Diabetes
• Hemoglobin A1C
• Osteoarthritis
• Glycolysis & the Krebs Cycle — interactive animation
• Insulin Signaling & GLUT4 — interactive animation

Back to Table of Contents

Featured Videos